EUVIMEDObjevte EUVIMED
Crossref

Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer

Fabiana Izidro A L Layng, Huiyu Ren, Nicole A Bakas, Dhanya R Panickar, Lester J Lambert iD, Maria Celeridad, Jiaqian Wu iD, Laurent De Backer, Preeti Chandrachud, Allison S Limpert, Mitchell Vamos, Apirat Chaikuad iD and 9 more

ACS Chemical Biology · 2026-03-20 · 21 (3) · 469-489

DOI: 10.1021/acschembio.5c00711 ↗

At a glance

Journal article in ACS Chemical Biology, published online on 2026-02-12. Written by Fabiana Izidro A L Layng and 20 co-authors. Institution: Center for Therapeutics Discovery, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, Unit…. Major MEDLINE topics: Autophagy, Carcinoma, Non-Small-Cell Lung, Autophagy-Related Protein-1 Homolog, Protein Kinase Inhibitors. Cited 2 times so far (Crossref); 63 references. Funded by: NCI NIH HHS, Janssen Research and Development, National Cancer Institute.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including nonsmall cell lung cancer (NSCLC). We previously reported SBP-7455, a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2 and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501, two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, either as a single agent or in combination with current therapies.

Subjects

MeSH terms (MEDLINE)

AutophagyCarcinoma, Non-Small-Cell LungAutophagy-Related Protein-1 HomologProtein Kinase InhibitorsLung NeoplasmsProtein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsAntineoplastic AgentsHistocompatibility Antigens Class IHumansUp-RegulationCell Line, TumorA549 Cells

Substances

Autophagy-Related Protein-1 HomologProtein Kinase InhibitorsULK1 protein, humanProtein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsUlk2 protein, humanAntineoplastic AgentsHistocompatibility Antigens Class I

Authors and institutions

  • Center for Therapeutics Discovery, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
  • Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe-University Frankfurt, Frankfurt 60438, Germany.
  • Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt 60438, Germany.
  • Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California 92037, United States.

ORCID profiles: Lester J Lambert, Jiaqian Wu, Apirat Chaikuad, Stefan Knapp, Guy S Salvesen, Nicholas D P Cosford

Funding

  • NCI NIH HHS
  • Janssen Research and Development
  • National Cancer Institute
  • Bayer
  • Genentech
  • Takeda Pharmaceutical Company
  • Pfizer
  • Bristol-Myers Squibb

Cite

APA

Layng, F. I. A. L., Ren, H., Bakas, N. A., Panickar, D. R., Lambert, L. J., Celeridad, M., Wu, J., De Backer, L., Chandrachud, P., Limpert, A. S., Vamos, M., Chaikuad, A., Verdugo, B. B., Hagan, P. M., Brun, S. N., Tautz, L., Knapp, S., Shaw, R. J., Salvesen, G. S., …, & Cosford, N. D. P. (2026). Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer. ACS Chemical Biology, 21(3), 469-489. https://doi.org/10.1021/acschembio.5c00711

Vancouver

Layng FIAL, Ren H, Bakas NA, Panickar DR, Lambert LJ, Celeridad M, et al. Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer. ACS Chemical Biology. 2026;21(3):469-489. doi:10.1021/acschembio.5c00711

BibTeX
@article{Layng2026,
  author = {Layng, Fabiana Izidro A L and Ren, Huiyu and Bakas, Nicole A and Panickar, Dhanya R and Lambert, Lester J and Celeridad, Maria and Wu, Jiaqian and De Backer, Laurent and Chandrachud, Preeti and Limpert, Allison S and Vamos, Mitchell and Chaikuad, Apirat and Verdugo, Betsaida B and Hagan, Patrick M and Brun, Sonja N and Tautz, Lutz and Knapp, Stefan and Shaw, Reuben J and Salvesen, Guy S and Sheffler, Douglas J and Cosford, Nicholas D P},
  title = {Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer},
  journal = {ACS Chemical Biology},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {469--489},
  doi = {10.1021/acschembio.5c00711}
}
Start for free →